Posted by Michael Wonder on 09 Nov 2023
Takeda receives US FDA approval of Fruzaqla (fruquintinib) for previously treated metastatic colorectal cancer
8 November 2023 - Fruzaqla is the first targeted therapy approved for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade.
Takeda today announced that the US FDA has approved Fruzaqla (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
